HCPLive

Drug Reduces Brain Lesions in Multiple Sclerosis

Tuesday, April 17 (HealthDay News) -- As part of a Phase 2 trial, Timothy Vollmer, M.D., from the University of Colorado in Denver, and colleagues randomly assigned 407 patients with relapsing-remitting MS to placebo or one of three doses of ONO-4641 (0.05 mg, 0.10 mg, or 0.15 mg) once a day for 26 weeks. Participants were aged 18 to 55 years and had Expanded Disability Status Scale scores up to 5.5.

Based on brain scans performed every four weeks starting at week 10, the researchers found that, compared with placebo, there was a reduction in gadolinium-enhancing lesions of 82 percent for the 0.05 mg dose, 92 percent for the 0.10 mg dose, and 77 percent for the 0.15 mg dose. Adverse events appeared to be dose related and included cardiovascular events, liver enzyme elevations, and grade 4 lymphopenia.

"ONO-4641 demonstrated statistically significant efficacy on key end points, compared to placebo, and was well tolerated in patients with relapsing-remitting MS," Vollmer and colleagues conclude.

The study was supported by Ono Pharmaceutical Co., Ltd., which developed ONO-4641.

Press Release
More Information

An experimental drug, ONO-4641, which is an oral sphingosine-1-phosphate receptor agonist, reduces the number of brain lesions in patients with relapsing-remitting multiple sclerosis, according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 28 in New Orleans.

Copyright © 2012 HealthDay. All rights reserved.

Most Popular

Recommended Reading

For patients with transsphenoidal pituitary tumors, hospital charges, costs, and length of stay are increased with lower-volume surgeons, according to a study presented at the annual meeting of the American Association of Neurological Surgeons, held from May 2 to 6 in Washington, D.C.

For patients undergoing single-level lumbar discectomy, preoperative working status is the strongest predictor of return to work at three months, according to a study presented at the annual meeting of the American Association of Neurological Surgeons (AANS), held from May 2 to 6 in Washington, D.C.

For patients undergoing lumbar spine surgery for degenerative disease, patient-reported measures of treatment effectiveness obtained at three months correlate with, but do not reliably predict, 12-month measures, according to a study presented at the annual meeting of the American Association of Neurological Surgeons (AANS), held from May 2 to 6 in Washington, D.C.

The next step in reducing and preventing neuropathic pain has been identified, according to researchers from UC Davis.
$vAR$